Table 2 Clinical characteristics of the patients in the RNA sequencing cohort

Age (years), median [Q1, Q3]

48.0 [43.5, 53.0]

42.0 [39.0, 47.5]

45.5 [35.8, 48.8]

Female (%)

3 (20.0)

3 (21.4)

1 (10.0)

Male (%)

12 (80.0)

11 (78.6)

9 (90.0)

HBV DNA level (IU/ml)

≤ 2 × 10^2

15

13

–

2 × 10^2–2 × 10^6

0

2

–

> 2 × 10^6

0

0

–

Antiviral therapy (%)

15 (100)

13 (86.7)

–

Laboratory data, mean (SD)

Albumin (g/L)

47.8 (3.4)

48.8 (2.1)

46.8 (2.7)

Globulin (g/L)

26.9 (3.6)

26.7 (2.2)

25.7 (2.4)

Total bilirubin (µmol/L)

17.6 (6.3)*

15.8 (6.2)*

13.1 (5.2)

Direct bilirubin (µmol/L)

6.0 (2.7)*

5.6 (3.2)*

3.6 (1.6)

Indirect bilirubin (µmol/L)

11.6 (4.8)

9.2 (3.4)

9.6 (4.7)

Alanine aminotransferase (U/L)

23.2 (11.9)

32.8 (15.0)**

30.8 (16.1)

Aspartate aminotransferase (U/L)

24.6 (8.1)

24.7 (6.9)

25.1 (9.1)

Alkaline phosphatase (U/L)

86.5 (30.0)

74.5 (16.1)

73.8 (20.5)

γ-Glutamyl transpeptidase (U/L)

36.4 (36.7)

19.9 (9.2)

31.6 (11.6)

Total bile acid (µmol/L)

7.4 (5.6)

4.2 (1.7)

5.6 (3.0)

Triglyceride (mmol/L)

1.1 (0.6)

1.1 (0.3)

2.8 (2.1)

Total cholesterol (mmol/L)

4.3 (0.9)*

4.4 (0.6)*

3.4 (1.9)

Creatinine (µmol/L)

70.9 (15.3)

76.3 (19.4)

74.8 (13.3)

Blood urea nitrogen (mmol/L)

5.2 (1.3)

4.9 (1.4)

5.3 (1.0)

K⁺ (mmol/L)

4.2 (0.4)

4.1 (0.2)

4.3 (0.3)

Na⁺ (mmol/L)

142.6 (2.1)

142.1 (1.8)

142.8 (3.5)

INR

1.0 (0.0)

0.9 (0.0)

–

White blood cells (*10^9/L)

5.5 (1.9)

5.5 (1.0)

5.5 (1.2)

Hemoglobin (g/L)

151.6 (13.2)

148.0 (13.1)

154.1 (12.4)

Platelets (*10^12/L)

160.7 (59.6)**

181.8 (53.7)*

220.9 (25.7)